Solomon Moshkevich Sells 293 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 293 shares of Natera stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total value of $68,855.00. Following the completion of the transaction, the insider owned 144,699 shares in the company, valued at approximately $34,004,265. This represents a 0.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total transaction of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $193,858.56.

Natera Trading Down 0.5%

NTRA stock opened at $241.58 on Friday. The stock has a market capitalization of $33.42 billion, a price-to-earnings ratio of -105.49 and a beta of 1.62. The firm’s 50-day moving average price is $234.18 and its two-hundred day moving average price is $191.17. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36.

Natera (NASDAQ:NTRA) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period in the previous year, the business earned ($0.26) earnings per share. The firm’s revenue for the quarter was up 34.7% compared to the same quarter last year. Equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Investors Weigh In On Natera

Several hedge funds have recently bought and sold shares of NTRA. Rakuten Investment Management Inc. purchased a new position in shares of Natera in the 3rd quarter worth about $34,096,000. SWS Partners increased its stake in Natera by 11.8% during the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after purchasing an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after buying an additional 5,614 shares during the last quarter. Baird Financial Group Inc. raised its holdings in Natera by 277.8% in the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after buying an additional 19,576 shares during the last quarter. Finally, Orion Porfolio Solutions LLC lifted its stake in shares of Natera by 68.8% in the second quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after buying an additional 4,946 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NTRA. BNP Paribas Exane raised Natera to a “hold” rating and set a $172.00 price target for the company in a research note on Monday, October 27th. Barclays upped their price objective on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Guggenheim lifted their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Citigroup started coverage on shares of Natera in a research note on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price target for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.